Skip to content

Hemodynamic Changes of Spinal Anesthesia in Pre-eclampsia

Comparison the Hemodynamic Effects of Spinal Anesthesia with Bupivacaine-Fentanyl in Pre-eclamptic Versus Normal Pregnant women

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT201304157695N3
Enrollment
70
Registered
2013-07-23
Start date
2010-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-eclampsia. Moderate Pre-eclampsia

Interventions

Intervention 1: In the first group (normal pregnant patients), 2 ml bupivacaine 0.5% (trademark marcaine, made in Merck factory in France) and 2 ml fentanyl (20µg) was administered intrathecally as a
Prevention
In the first group (normal pregnant patients), 2 ml bupivacaine 0.5% (trademark marcaine, made in Merck factory in France) and 2 ml fentanyl (20µg) was administered intrathecally as a single dose.
In the second group (pre-eclamptic patients), 2 ml bupivacaine 0.5% (trademark marcaine, made in Merck factory in France) and 2 ml fentanyl (20µg) was administered intrathecally as a single dose.

Sponsors

Vice-Chancellor for Research of Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Pregnant women with age range of 18-45 years old Exclusion criteria: Patient refusal of spinal anesthesia, presence of: fetal distress, convulsion, pulmonary edema, headache, visual impairment, impaired consciousness, coagulopathy, high systemic blood pressure (BP>170/110), systemic involvement (diabetes mellitus, chronic hypertension), positive history of antihypertensive drugs consumption

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Blood pressure and heart rate. Timepoint: After spinal anesthesia, every 5 minutes during operation until 30 minutes after operation in recovery period. Method of measurement: By noninvasive cardiovascular monitoring, blood pressure and heart rate were measured and recorded in questionnaire.

Secondary

MeasureTime frame
Shivering. Timepoint: Recovery period. Method of measurement: By observational method (mild, moderate and sever) was determined and recorded in questionnaire.;Nausea, vomiting. Timepoint: During operation until 30 minutes after operation in recovery period. Method of measurement: By observational method (mild, moderate and sever) was determined and recorded in questionnaire.;Postoperative Pain. Timepoint: During 30 minutes after operation in recovery period. Method of measurement: By Visual Analog Scale was determined and recorded in questionnaire.;Apgar score. Timepoint: First and fifth minute. Method of measurement: By numbering method (1-10) was determined and recorded in questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Abbas Hosseini Jahromi M.D.

Qazvin University of Medical Sciences

sahosseinij@qums.ac.ir+98 28 1332 0107

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026